Who are Hydroxyzine HCL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antihistamine Cetirizine Hydrochloride, montelukast and cetirizine, Morphine-Promethazine, Fluticasone/Azelastine nasal spray, Ciclesonide & Levocetirizine, fexofenadine HCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxyzine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Hydroxyzine HCL — Competitive Intelligence Brief

Hydroxyzine HCL (Hydroxyzine HCL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: First-generation H1 antihistamine. Area: Psychiatry, Dermatology, Allergy/Immunology.

marketed First-generation H1 antihistamine H1 histamine receptor Psychiatry, Dermatology, Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxyzine HCL (Hydroxyzine HCL) — National Cancer Institute (NCI). Hydroxyzine is a first-generation antihistamine that blocks H1 receptors to reduce histamine-mediated allergic and anxiety responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hydroxyzine HCL TARGET	Hydroxyzine HCL	National Cancer Institute (NCI)	marketed	First-generation H1 antihistamine	H1 histamine receptor
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	Goldman, Butterwick, Fitzpatrick and Groff	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
montelukast and cetirizine	montelukast and cetirizine	Medical University of Lodz	marketed	Leukotriene receptor antagonist and H1-receptor antagonist combination	CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
Ciclesonide & Levocetirizine	Ciclesonide & Levocetirizine	Handok Inc.	marketed	Inhaled corticosteroid + selective H1-receptor antagonist combination	Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine)
fexofenadine HCl	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (First-generation H1 antihistamine class)

National Cancer Institute (NCI) · 1 drug in this class
University Hospital, Toulouse · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxyzine HCL — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxyzine-hcl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab